<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204644">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000328</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-11160-3</org_study_id>
    <secondary_id>1R01DA011160</secondary_id>
    <secondary_id>R01-11160-3</secondary_id>
    <nct_id>NCT00000328</nct_id>
  </id_info>
  <brief_title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3</brief_title>
  <official_title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical efficacy of the buprenorphine/naloxone
      combination tablet to methadone for opioid maintenance treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      S/A brief &quot;Summary for the Public&quot;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1997</start_date>
  <completion_date type="Actual">August 1997</completion_date>
  <primary_completion_date type="Actual">August 1997</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Drug use</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid agonist rating</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid antagonist rating</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication identification</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Addiction Severity Index (ASI) Composite Score Rating</measure>
  </primary_outcome>
  <enrollment>0</enrollment>
  <condition>Heroin Dependence</condition>
  <condition>Opioid-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opioid-Related Disorders</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Individuals must be at least 18 years of age, currently opioid dependent and meet FDA
        criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence
        disorders may also be present. Individuals must be healthy despite drug dependency.

        Exclusion Criteria:

        Individuals with evidence of an active Diagnostic and Statistical Manual of Mental
        Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness,
        organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular
        disease) or pregnant female subjects are excluded from study participation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Amass, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>May 26, 2015</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug dependence</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heroin Dependence</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
